Levodopa and Benserazide Tablets 0.25g

Levodopa and Benserazide Tablets 0.25g

$1.00

Levodopa and Benserazide Tablets (brand: Weiliding ) combine Levodopa (200?mg) and Benserazide Hydrochloride (50?mg) per tablet. Supplied in boxes of 40 tablets, this formulation is ideal for laboratory use in neurological research on dopaminergic pathways, Parkinson’s disease, and motor control studies.?? Strictly for laboratory research use only.?Please consult staff for other specifications and uses?

EMI starting from $0.00/month - View Plans

Description

This fixed-dose combination of Levodopa and Benserazide is a gold standard model compound for experimental studies of Parkinson’s disease, particularly in understanding dopamine biosynthesis, metabolism, and central nervous system neurotransmission.

Benserazide acts as a DOPA decarboxylase inhibitor, enhancing Levodopa’s bioavailability in the brain while reducing peripheral side effects—making this pairing useful for controlled experimental models in pharmacological and neuroscience research.


Levodopa and Benserazide Product Specifications

ParameterDetails
Product NameLevodopa and Benserazide Tablets
Brand NameWeiliding
Active IngredientsLevodopa (200?mg) + Benserazide Hydrochloride (50?mg)
CAS NumberLevodopa: 59-92-7; Benserazide: 14919-77-8
Molecular FormulaLevodopa: C9H11NO4; Benserazide: C10H15N3O5
Molecular WeightLevodopa: 197.19 g/mol; Benserazide: 257.24 g/mol
Dosage FormOral tablet
Strength0.25g (200?mg/50?mg) per tablet
Pack Size40 tablets per box
Approval NumberH20243207 (NMPA, China)
Drug Code86904647001508
ManufacturerZhejiang Huahai Pharmaceutical Co., Ltd.
Barcode6958439004691
Storage ConditionsStore below 25°C; protect from moisture and light
Intended UseLaboratory research only

Levodopa and Benserazide Mechanism of Action

  • Levodopa serves as a direct precursor to dopamine. It crosses the blood-brain barrier and is converted to dopamine in the central nervous system, restoring dopaminergic function.

  • Benserazide is a peripheral decarboxylase inhibitor, preventing Levodopa from premature conversion into dopamine outside the brain—enhancing central activity while reducing side effects.

This synergistic action is frequently studied in Parkinsonian rodent models, motor learning simulations, and dopamine pathway mapping.


Research Applications

  • Parkinson’s Disease Models
    Evaluate Levodopa’s effects on motor control, bradykinesia, tremors, and muscle rigidity in animal models.

  • Dopamine Pathway Studies
    Analyze synaptic dopamine release, receptor activation, and neuroadaptive responses to long-term administration.

  • Drug Interaction Studies
    Test interactions between dopamine agonists, anticholinergics, and MAO-B inhibitors in polypharmacy research settings.

  • Neurotoxicity and Side Effect Profiling
    Assess long-term neurochemical and behavioral changes, including potential dyskinesias or tolerance.


Safety & Handling

  • Handling Instructions: Use gloves and PPE. Avoid skin or mucosal exposure.

  • Storage: Keep sealed in original packaging. Store below 25?°C.

  • Shelf Life: 24–36 months under standard research storage conditions.

  • Toxicological Caution: High-dose exposure may alter neurotransmitter balance in test subjects—monitor carefully during extended studies.


Research Use Disclaimer

This product is designated solely for scientific laboratory research purposes. It is not to be used in humans, animals, or for diagnostic or therapeutic applications. Users must follow all institutional and legal compliance for handling and storage.

Additional information

Weight1 kg
Dimensions26 × 23 × 26 cm

Reviews

There are no reviews yet.

Be the first to review “Levodopa and Benserazide Tablets 0.25g”

Your email address will not be published. Required fields are marked *

Q1: What are the CAS numbers of Levodopa and Benserazide?

A1: Levodopa – CAS 59-92-7; Benserazide – CAS 14919-77-8

Q2: Is this formulation suitable for Parkinson’s research?

A2: Yes, it’s widely used in preclinical studies related to Parkinson’s disease, dopamine deficiency, and neurodegeneration models.

Q3: Can I order in bulk quantities?

A3: Yes, we support bulk orders and B2B procurement for academic institutions, pharmaceutical R&D, and laboratories.

Q4: Do you provide COA or regulatory documents?

A4: Yes, Certificate of Analysis (COA) and SDS documents are available on request.

Q5: Can this product be used in clinical settings?

A5: No. This product is not approved for human or therapeutic use. It is strictly intended for laboratory research.


EMI Options